Difference between revisions of "Paliperidone LA-Amisulpride"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{NAY}}')
 
Line 1: Line 1:
 
{{NAY}}
 
{{NAY}}
 +
{{switch-to-(9OH-)risperidone}}

Revision as of 10:29, 6 May 2011

Paliperidone palmitate is since spring 2011 approved by EMEA: therefore this switch is under construction.

There are 2 switch possibities:

Number 1 (the general approach):

  • Day 1: Switch to oral risperidone (or oral paliperidone): see this switch in the main cross table.
  • Day 1-29: Maintain on oral risperidone (or oral paliperidone) and examine the effects.
  • Day 30: stop oral risperidone (or oral paliperidone) and administer paliperidone-LA: see this switch in the main cross table.

Oral risperidone has better and more stable bioavailability properties than has oral 9-OH-risperidone=paliperidone. Food increases the absorption with 50-60% of the latter.


Number 2 (if a patient in the past reacted well on risperidon or paliperidone=9-OH-risperidone):